{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:34:27Z","timestamp":1774402467187,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Data on octogenarian patients with MM are scarce, and optimal management remains controversial. We report a retrospective cohort of unselected octogenarian patients with NDMM treated with bortezomib dexamethasone (Vd). Seventy-four patients were treated with an initial doublet therapy (Vd regimen, 2\u20133 cycles, induction). A dose escalation with an adjunction of melphalan or cyclophosphamide was proposed for patients who had an insufficient response after induction and who could tolerate it. In responders, the treatment was continued until progression or a plateau response for 6 months (consolidation). The overall response rate was 73%. After a median follow-up of 31.4 months, median progression-free survival (PFS) and overall survival (OS) were 13.2 and 26.9 months, respectively. PFS and OS of patients with ECOG PS &lt; 3 (25.4 and 54.9 months, respectively) were better in comparison to PFS and OS of patients with ECOG PS \u2265 3 (9.3 and 11.3 months, respectively). Thirteen patients (17.6%) died during induction. Twelve patients (16.2%) died during consolidation. In conclusion, a conservative therapeutic strategy based on Vd resulted in a good response rate. However, the survival remains poor in the population of patients with an ECOG PS \u2265 3, mainly because of early mortality not related to progressive disease.<\/jats:p>","DOI":"10.3390\/cancers14194741","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T20:58:47Z","timestamp":1664398727000},"page":"4741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature"],"prefix":"10.3390","volume":"14","author":[{"given":"Laurence","family":"Huynh","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudy","family":"Birsen","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, H\u00f4pital Cochin, APHP, Universit\u00e9 de Paris Cit\u00e9, 75014 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Mora","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-2201","authenticated-orcid":false,"given":"Anne-Laure","family":"Couderc","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Mitha","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Farcet","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amale","family":"Chebib","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Chaibi","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Oncologie G\u00e9riatrique, H\u00f4pital Charles Foix, APHP, 94200 Ivry Sur Seine, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_10","unstructured":"Institut National du Cancer (Sant\u00e9 Publique France Rapport, 2019). Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018\u2014Volume 2 H\u00e9mopathies malignes, Sant\u00e9 Publique France Rapport."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2016.36","article-title":"A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma","volume":"30","author":"Larocca","year":"2016","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"Laubach","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2012.01784.x","article-title":"Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era","volume":"89","author":"Dimopoulos","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2012.259","article-title":"Treatment patterns and outcomes in elderly patients with multiple myeloma","volume":"27","author":"Bang","year":"2013","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2015.1041386","article-title":"Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: Comparison with patients in different age groups in the era of novel agents","volume":"57","author":"Matsue","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bjh.16095","article-title":"Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: A retrospective multi-centre analysis of real-world data","volume":"187","author":"Chan","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3324\/haematol.2017.173617","article-title":"Treat or palliate: Outcomes of very elderly myeloma patients","volume":"103","author":"Panitsas","year":"2018","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10428194.2018.1509323","article-title":"Vulnerability variables among octogenerian myeloma patients: A single-center analysis of 110 patients","volume":"60","author":"Gavriatopoulou","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.15848","article-title":"The combination of an inclusive novel agent treatment strategy, pre-emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients","volume":"186","author":"Ediriwickrama","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study","volume":"39","author":"Stege","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Medhekar, R., Ran, T., Fu, A.Z., Patel, S., and Kaila, S. (2022). Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09980-9"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/agm2.12045","article-title":"Factors associated with medication adherence in older patients: A systematic review","volume":"1","author":"Smaje","year":"2018","journal-title":"AGING Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2015.133629","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Dimopoulos","year":"2016","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): A multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","article-title":"Safety considerations of fluoroquinolones in the elderly: An update","volume":"27","author":"Stahlmann","year":"2010","journal-title":"Drugs Aging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:26Z","timestamp":1760143286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":32,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194741"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194741","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}